NeuroVive employs a Clinical Trial Manager

NeuroVive Pharmaceutical AB (publ) has recruited Gunilla Lindgren to the
position as Clinical Trial Manager. The recruitment enables NeuroVive to ensure
the sustained high quality and efficient operations of its ongoing and future
clinical trials as it continues to expand. Gunilla Lindgren has solid experience
of similar positions with an international focus at Astra Zeneca and Quintiles.
NeuroVive is currently in a strong growth phase with several international
clinical studies and promising drug candidates in pre-clinical development. This
means that the company expects the high level of activity in clinical trials to
continue over the coming years. Accordingly, NeuroVive’s management has decided
to recruit Gunilla Lindgren to the position as clinical trial manager. Gunilla
will be responsible for ensuring the efficiency and high quality of clinical
trials within the timeframes and budgets of NeuroVive’s projects.

Gunilla Lindgren has solid experience of similar positions in leading
international pharmaceutical companies such as Astra Zeneca and Quintiles. She
will take up her position on 21 December 2014.

“This recruitment enables NeuroVive to continue its current expansion phase and
to ensure the high quality of its current and future clinical trials. Gunilla
Lindgren’s experience from major international companies will be extremely
valuable in this process, and I’m delighted to welcome her to NeuroVive,”
commented Jan Nilsson, NeuroVive’s COO.

“It’s exciting and challenging to be participating in running even more
effective and scalable clinical trials in an innovative and expansive company
like NeuroVive. I think I’ll fit in well in this process, as I’ll be able to
combine my experience of larger companies with NeuroVive’s strong drive,”
commented Gunilla Lindgren.

About NeuroVive Pharmaceutical

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of brain cell injury in stroke
patients, and drug candidates for cellular protection and treating mitochondria
-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ
OMX, Stockholm, Sweden.

For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting (http://www.laika.se), Tel: +46 (0)46 275 62
21 or ir@neurovive.se. It is also possible to arrange an interview with
NeuroVive’s CEO Mikael Brönnegård or COO Jan Nilsson at the above contact.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard),
Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 8 December 2014, at 8.30 a.m. CET.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Grey Market. Investors can find
Real-Time quotes and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt//www.otcmarkets.com/stock/NE
V 
PF/quot)